Johns wort affects CYP3A4 but since retatrutide doesnt use CYP metabolism, no interaction is expected
GLP-1 medications are approved for adults who have a body mass index (BMI) of 30 or higher, or a BMI of at least 27 plus a weight-related medical condition, such as the following: Type 2 diabetes High blood pressure High cholesterol Obstructive sleep apnea Cardiovascular disease that increases the risk of heart attack or stroke MASH, or metabolic dysfunctionassociated steatohepatitis, a form of liver inflammation Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine, notes that qualifying for the medication based on heart disease aloneoften necessary for insurance coveragecan be challenging
Winter considerations Freezing is the bigger risk in winter
P., Cristaldi, E., Vacante, M., Risino, C., Cammalleri, L., Pennisi, G., and Rampello, L
In 119 G6PD-deficient (hemizygous or homozygous) children with malaria who received 7.5 mg/kg of dapsone over 3 days, the drop in hemoglobin averaged about 2 g/dL, with a nadir on day 7